GYRE vs PATH · rev $105.8M vs P/E 19, rev $1.61B
Gyre Therapeutics Inc. (GYRE) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Gyre Therapeutics Inc. (GYRE) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported GYRE revenue for 2024-12-31 was $105.8M. Net income was $17.9M. Revenue was down 6.8% from 2023-12-31 to 2024-12-31. GYRE currently screens at market cap $589.9M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
GYRE currently screens at market cap $589.9M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the GYRE and PATH stock pages for the full models.
Not investment advice.